Fundz Deep Dive
Everything you need to win Royalty Pharma plc — in one platform.
Who to reach, what to say, and why now on Royalty Pharma plc — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Royalty Pharma plc — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Royalty Pharma Partners with Teva to Fund Development of TEV-‘408 with Up to $500 Million.
Jan 11, 2026•5 months ago
Contract Type
partnership
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Royalty Pharma has entered into a partnership with Teva Pharmaceuticals to provide up to $500 million in funding for the anti-IL-15 antibody TEV-‘408, aimed at treating autoimmune diseases. This funding will support critical phases of clinical development as part of Teva's growth strategy.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months